Can airduo be used for copd?

Can Airduo be used for COPD?

Airduo is a combination inhaler containing fluticasone, a corticosteroid, and salmeterol, a long-acting beta agonist. It is approved for the treatment of asthma in patients 12 years and older. It is not approved for COPD.

Why does the FDA limit its use to asthma only?

The FDA approved Airduo only for asthma because clinical trials focused on asthma patients. Those trials showed that the combination of fluticasone and salmeterol reduces asthma attacks and improves lung function in that population. No equivalent trials established safety or efficacy for COPD.

What happens if someone takes Airduo for COPD?

Patients who use Airduo for off-label purposes may experience the gleichen effects seen in asthma, such as improved breathing through bronchodilation and inflammation reduction. However, the manufacturer warns against using it for COPD due to lack of specific data. Off-label use carries risk of side effects without the guidance of dedicated studies.

How does Airduo compare with COPD-approved inhalers?

COPD-approved inhalers such as Advair, Symbicort, and Spiriva contain similar active ingredients or different mechanisms. Advair contains the same active ingredients as Airduo. Advair has explicit approval for COPD in a higher fluticasone dose. Higher-dose versions of Airduo may offer similar effects, but FDA approval differs between the products.

When does the Airduo patent expire?

The Airduo patent expires in 2023.